1Arroyo V,Gines P,Gerbes AL,et al.Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis[J].Hepatology,1996,23 (1):164-173. 被引量：1
2Woitas RP,Flommersfeld S,Stoffel-Wagner B,et al.Renal functional reserve is well maintained in patients with advanced liver cirrhosis and ascites[J].Scand J Gastroenterol,2002,37(11):1321-1327. 被引量：1
6Gines P,Uriz J,Calahorra B,et al.Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis[J].Gastroenterology,2002,123(6):1839-1847. 被引量：1
7Bilbao JI,Quiroga J,Herrero JI.Transjugular intrahepatic portosystemic shunts (TIPS):current status and future posibilities[J].Cardiovasc Intervent Padiol,2002,25 (4):251-269. 被引量：1
8Wroblewski T,Rowinski D,Pawlak J,et al.Intrahepatic portosystemic shunt in treatment of complications of portal hypertension[J].Med Sci Monit,2001,7(suppl 1):315-310. 被引量：1
9Solanki P,Chawla A,Garg R,et al.Benefical effects of terlipressin in hepatorenal syndrome:a prospective randomized placebo-controlled clinical trial[J].Gastroenterol Hepatol,2003,18(2):152-156. 被引量：1
10Ortega R,Gines P,Urig J,et al.Terlipressin therapy with and without albumin for patients with hepatorenal syndrome:result of a prospective,nonrandomized study[J].Hepatology,2002,36(4 ptl):941-948. 被引量：1
2Ruiz-Cabello F,Garrido F.HLAand cancer:Fromresearch to clinical impact[].Immunology Today.1998 被引量：1
3Sung CH,Hu CP,Hsu HC,Ng AK,Chou CK,Ting LP,Su TS,Han SH,Chang CM.Expression of class Ⅰ and class Ⅱ major histocompatibility antigens on human hepatocellular carcinoma[].The Journal of Clinical Investigation.1989 被引量：1
4Wadee A A,Paterson A,Coplan KA,Reddy SG.HLA expression in hepatocellular carcinoma lines[].Clinical and Experimental Immunology.1994 被引量：1
5Alexander,JJ,Bey,EM,Geddes,EW,Lecatsas,G.Establishment of a continuously growing cell line from primary carcinoma of the liver[].South African Medical Journal.1976 被引量：1
6Aden,DP,Fogel,A,Plotkin,S,Damjanov,I,Knowles,BB.Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line[].Nature.1979 被引量：1
7Jr,Vollmer,CM,Eilber,FC,Butterfield,LH,Ribas,A,Dissette,VB,Koh,A,Montejo,LD,Lee,MC,Andrews,KJ,McBride,WH,Glaspy,JA,Economou,JS.Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma[].Cancer Research.1999 被引量：1
8Butterfield,LH,Koh,A,Meng,W,Vollmer,CM,Ribas,A,Dissette,V,Lee,E,Glaspy,JA,McBride,WH,Economou,JS.Generation of Human T-cell Responses to an HLA-A2.1-restricted peptide epitope derived from alpha-Fetoprotein[].Cancer Research.1999 被引量：1
9Butterfield L,Meng W,Koh A,et al.T cell responses to HLA-A* 0201-restricted peptides derived from human alpha-fetoprotein[].J Immunol.2001 被引量：1
10Paterson AC,Sciot R,Kew MC,Callea F,Dusheiko GM,Desmet VJ.HLA expression in human hepatocellular carcinoma[].British Journal of Cancer.1988 被引量：1
9[2]Schrier RW,Arroyo V,Bermardi M,etal.Peripheral art erial vasodilatation hypothesis:a proposal for the initiation of renal sodium and water retention on cirrhosis[J].Hepatology,1988,(8):1151. 被引量：1
10[9]Pehl C,Sehepp W.Sueeessful therapy of hepatorenal syndrome with norepinephrine Z Gasttoenterol,2000,(38):945-950. 被引量：1
